 REDWOOD CITY, Calif., Sept. 27, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal IVT injection gene therapy from the OPTIC trial in wet age-related macular degeneration wet AMD and the INFINITY trial in diabetic macular edema DME at upcoming medical conferences. Adverum is planning clinical development of ADVM-022 at the 2 x 1011 vgeye and a lower dose in patients with wet AMD. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME. 